News >

Avelumab Falls Short in Frontline Ovarian Cancer Trial

OncLive Staff
Published: Wednesday, Dec 26, 2018

The phase III JAVELIN Ovarian 100 study exploring frontline avelumab (Bavencio) in ovarian cancer has been ended after an independent panel determined the study would not meet its primary endpoint of progression-free survival (PFS), according to Merck KGaA and Pfizer, the co-developers of the PD-L1 inhibitor. 

This is the second recent report of a phase III trial of avelumab in ovarian cancer that has missed its primary endpoint. Last month, Merck KGaA and Pfizer reported that findings from the phase III JAVELIN Ovarian 200 trial showed that avelumab alone or in combination with pegylated liposomal doxorubicin (PLD) did not induce a statistically significant improvement in overall survival (OS) or PFS versus PLD alone in patients with platinum–resistant/refractory ovarian cancer, missing the primary endpoints of the study

Avelumab plus PLD led to an HR for PFS of 0.78, which did not meet the prespecified criteria for superiority (repeated confidence interval [RCI], 0.587-1.244; one-sided P value = .0301). The OS endpoint with the avelumab combination was also not met (HR, 0.89; RCI, 0.744-1.241; one-sided P value = .2082).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication